Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $123

Benzinga Newsdesk www.benzinga.com Negative 89.5%

Neg 89.5% Neu 0% Pos 0%

Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $130 to $123.